SeaStar Medical Holding Corporation (ICUCW) 株式分析

企業概要

SeaStar Medical Holding Corporation is a commercial-stage medical device company that focuses on developing proprietary platform therapies designed to mitigate the consequences of hyperinflammation on vital organs within the United States market. The company operates primarily in the medical device sector, specifically targeting disease-modifying devices such as its selective cytopheretic device (SCD), which aims to alter the course of inflammatory conditions. According to the available data, the company employs 17 individuals and reports a trailing twelve-month revenue of $1.23M, though specific market capitalization, sector classification, and industry categorization are not disclosed in the current dataset. The reported annual revenue of $1.23M indicates that the entity operates at a relatively small scale, likely serving a niche segment of the broader medical device industry where specialized innovation often precedes mass-market commercialization.

財務健全性

The company generated $1.23M in revenue over the trailing twelve months, yet reported a net income of -$12,150,000 and an EBITDA figure that is not available for calculation. This substantial gap between positive revenue and significant net losses reveals a cost structure where operating expenses and other deductions far exceed the income generated from sales, a common characteristic in early-stage development companies before achieving profitability. Furthermore, the free cash flow stands at -$9,391,750, which indicates that the company is consuming cash reserves to fund its operations and development activities rather than generating surplus liquidity. The gross margin is reported at an exceptionally high 95.7%, suggesting that the cost of goods sold is minimal relative to revenue, while the operating margin of -718.1% and profit margin of 0.0% highlight severe operational inefficiencies or high overhead costs relative to sales. In terms of balance sheet composition, the company holds $11.98M in cash against $525,000 in debt, resulting in a debt-to-equity ratio of 5.04, which suggests a highly leveraged position despite the significant cash buffer. The current ratio of 3.63 indicates that the company possesses ample short-term assets to cover its short-term liabilities, reflecting strong immediate liquidity despite the overall negative earnings. Additionally, the return on equity is -295.2% and the return on assets is -80.9%, metrics that reveal that management has not yet generated positive returns on shareholder investments or total assets due to the ongoing losses.

バリュエーション評価

Trailing P/E and forward P/E ratios are not available for SeaStar Medical Holding Corporation because the company is currently unprofitable, which implies that traditional earnings-based valuation multiples cannot be calculated or do not reflect expected earnings trajectories. The price-to-book ratio is recorded at 0.01, indicating that the market values the company's equity at a fraction of its book value, a situation often seen in loss-making firms where the market price is significantly below the net asset value. Price-to-sales and EV/EBITDA multiples are also not available, suggesting that alternative valuation metrics relying on profitability or enterprise value are not applicable given the current financial structure. The stock has traded within a 52-week range between a high of $0.03 and a low of $0.02, meaning the current price sits at the lower end of this historical trading band relative to the 52-week high. The beta value of -1.19 indicates that the stock price exhibits negative correlation with the broader market and possesses extreme volatility, moving inversely to market trends with a magnitude greater than average.

Growth & Income

Revenue growth year-over-year is reported at 526.9%, while earnings growth is not available due to the company's negative net income, implying that top-line expansion is occurring without corresponding bottom-line improvement. The company does not pay dividends, as evidenced by the absence of a dividend yield and payout ratio, which means that instead of distributing income to shareholders, the entity retains all earnings to fund its research and development initiatives. Consequently, the company's strategy involves reinvesting its limited resources into growth rather than providing current income to investors, a typical approach for commercial-stage medical device firms still in the loss-making phase. The overall growth and income profile is characterized by rapid revenue expansion coupled with significant cash consumption and an absence of dividend distribution or positive earnings growth.